BioStock: Pila Pharma takes final steps before toxicology studies

After this summer’s IPO, Malmö-based Pila Pharma is at full activity, preparing for the upcoming phase IIb study with drug candidate XEN-D0501. In its latest reached milestone, the company has completed GMP production of placebo tablets that will be used in the study, and the next step is to implement the toxicology program. BioStock contacted the company’s founder and CEO Dorte X. Gram to learn more about what lies ahead.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/09/pila-pharma-takes-final-steps-before-toxicology-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se